Rectal delivery of 89Zr-labeled infliximab-loaded nanoparticles enables PET imaging-guided localized therapy of inflammatory bowel disease

Rectal delivery of radiolabeled infliximab nanoparticles enabled PET imaging confirmation of colon targeting and prolonged retention at inflammation sites, while demonstrating comparable anti-inflammatory efficacy to intravenous antibody therapy.